MedTrace Logo

Switch of AndroidAPS to Commercially Available AID Systems

NCT06709729 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-11-29

No results posted yet for this study

Summary

The aim of the study was to investigate the switch between open-source automated insulin delivery system (OS-AID) - AndroidAPS (AAPS) and commercially available AID systems - Control-IQ (CIQ) and MiniMed 780G (780G) in extended follow-up study.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

Insulin pump with closed-loop system

Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS

Sponsors & Collaborators

  • General University Hospital, Prague

    collaborator OTHER

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Jan Soupal · 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2024-12-01
Completion
2024-12-31
FDA Device
Yes

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06709729 on ClinicalTrials.gov